27Serious

Biotech

Top News

Biotech, Markets

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

50% center coverage3 sources

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

Ask VT AI

View News Summary

Fed cuts rates, will replace maturing bonds with T-bills amid data blackout and softening labor market.
Starbucks reports first global same-store sales growth in seven quarters, but net income plunges due to restructuring costs.
Fed cuts rates, halts balance-sheet runoff amid slowing job gains and elevated inflation

20 hours

First 100 Days

See how you scored in predicting Trump's first 100 days

Latest News

Purple Biotech Shares Surge Over 90% After Tri-Specific Antibody Manufacturing Breakthrough

100% left coverage1 source

Purple Biotech Shares Surge Over 90% After Tri-Specific Antibody Manufacturing Breakthrough

100% left coverage1 source

Purple Biotech Shares Surge Over 90% After Tri-Specific Antibody Manufacturing Breakthrough

Purple Biotech Shares Surge Over 90% After Tri-Specific Antibody Manufacturing Breakthrough

PDS Biotech Seeks FDA Expedited Approval for HPV16-Positive Cancer Immunotherapy

100% left coverage1 source

PDS Biotech Seeks FDA Expedited Approval for HPV16-Positive Cancer Immunotherapy

100% left coverage1 source

PDS Biotech Seeks FDA Expedited Approval for HPV16-Positive Cancer Immunotherapy

PDS Biotech Seeks FDA Expedited Approval for HPV16-Positive Cancer Immunotherapy

Trinity Biotech Reports Perceptive Advisors Plans Debt-to-Equity Conversion to Strengthen Balance Sheet

100% left coverage1 source

Trinity Biotech Reports Perceptive Advisors Plans Debt-to-Equity Conversion to Strengthen Balance Sheet

100% left coverage1 source

Trinity Biotech Reports Perceptive Advisors Plans Debt-to-Equity Conversion to Strengthen Balance Sheet

Trinity Biotech Reports Perceptive Advisors Plans Debt-to-Equity Conversion to Strengthen Balance Sheet

Novartis Plans $12B Acquisition to Expand Neuroscience RNA Therapies

50% center coverage2 sources

Novartis Plans $12B Acquisition to Expand Neuroscience RNA Therapies

50% center coverage2 sources

Novartis Plans $12B Acquisition to Expand Neuroscience RNA Therapies

Novartis Plans $12B Acquisition to Expand Neuroscience RNA Therapies

Biotech, Markets

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

50% center coverage3 sources

Biotech, Markets

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

50% center coverage3 sources

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

Neurocrine Beats Q3, Reaffirms Ingrezza Guidance

IO Biotech Reports Promising Phase 3 Results for Cylembio and Keytruda in Advanced Melanoma

100% left coverage1 source

IO Biotech Reports Promising Phase 3 Results for Cylembio and Keytruda in Advanced Melanoma

100% left coverage1 source

IO Biotech Reports Promising Phase 3 Results for Cylembio and Keytruda in Advanced Melanoma

IO Biotech Reports Promising Phase 3 Results for Cylembio and Keytruda in Advanced Melanoma

Colossal Marks Dire Wolves' First Birthday

100% left coverage1 source

Colossal Marks Dire Wolves' First Birthday

100% left coverage1 source

Colossal Marks Dire Wolves' First Birthday

Colossal Marks Dire Wolves' First Birthday

Ask VT AI

View News Summary

Fed cuts rates, will replace maturing bonds with T-bills amid data blackout and softening labor market.
Starbucks reports first global same-store sales growth in seven quarters, but net income plunges due to restructuring costs.
Fed cuts rates, halts balance-sheet runoff amid slowing job gains and elevated inflation

20 hours

First 100 Days

See how you scored in predicting Trump's first 100 days

Most Reported By
News from Biotech